Mary Wambui, a 54-year-old tea picker on a Kericho plantation, earns roughly 8,000 to 12,000 Kenyan shillings a month—about US$60 to US$90. She has hypertension, diagnosed two years ago at a public health center. But when her doctor ordered a creatinine test to check her kidneys, the public clinic had no reagents. A private lab charged her 500 KES for the test, nearly a day's wage. She paid because she was afraid. This pattern is widespread across Kenya's tea-growing highlands, where an estimated 120,000 farm workers are hypertensive, according to a 2024 study by Moi University that screened 2,400 workers in 15 plantations. The study found that 72% of those with elevated blood pressure had not had a lab test in the previous six months. Public clinics stock blood pressure cuffs that gather dust while patients spend scarce cash on private lab tests.

A Farmer's Heart: Why Mary Paid for a Lab Test She Couldn't Afford

Mary's day starts at 5 a.m. She walks two kilometers to the tea fields, bends for hours plucking leaves, and carries a basket that weighs almost as much as she does. When she was diagnosed with hypertension, a nurse at the Kericho County Referral Hospital prescribed amlodipine, a common blood pressure drug, available free at public clinics. But the nurse also told her she needed regular blood tests—creatinine, electrolytes—to monitor for kidney damage, a common complication of untreated hypertension.

The public clinic near her home, a dispensary in the Kapsoit area, had a blood pressure cuff that worked, but the nurse said they had no reagents for the basic chemistry analyzer. "They told me to go to a private lab in town," Mary recalls. The nearest private lab is in Kericho town, a 30-minute matatu ride that costs 100 KES each way. The creatinine test alone was 500 KES. With transport, the total came to 700 KES—roughly 8% of her monthly income. Mary's story reflects a pattern documented by researchers. A 2024 survey of 12 primary health centers in Kericho County found that only three had functional blood pressure cuffs. Reagents for basic lab tests were out of stock for months at a time. Nurses told interviewers they referred patients to private labs daily. "We have the machines, but no reagents," one nurse said. "The cuffs are there, but we can't use them because the batteries are dead or the tubing is cracked."

The national hypertension prevalence in Kenya is estimated at 24% among adults, according to the World Health Organization. In Kericho, a county with a large tea plantation workforce, the rate may be higher because of the physical demands of the job and limited access to health care. Yet the health system meant to catch and manage the condition is failing at the most basic level.

Cuffs Silent on Shelves: How Public Facilities Fail to Monitor

Blood pressure cuffs are cheap, durable, and easy to use. A validated upper-arm cuff costs roughly 2,000 to 4,000 KES (US$15 to US$30). But in Kericho's public clinics, they are often missing or broken. A county health audit in early 2025 revealed that of 12 primary health centers surveyed, only three had a working BP cuff. One clinic had a cuff but no stethoscope. Another had a cuff that had been donated years ago and never used because staff had not been trained on it.

Reagents for basic labs are an even bigger problem. The public clinics in Kericho are supposed to offer creatinine, electrolyte, and urine protein tests for free under the Essential Package of Health Services. But supplies run out quickly and are not replenished for months. "We order reagents every quarter, but they arrive only once or twice a year," a nurse at a dispensary in the Ainamoi ward told me. "When we have them, we use them. When we don't, we refer."

The result is a system where patients like Mary must pay for tests that should be free. The irony is that the lab equipment—the analyzers—are often donated and functional. But without the consumables, they are glorified paperweights. "It's not a shortage of machines," said Dr. James Omondi, a public health researcher at Moi University who has studied hypertension care in western Kenya. "It's a shortage of systems to procure and distribute supplies."

Nurses in these clinics say they refer patients to private labs almost daily. "We feel bad," one nurse said. "But what can we do? We cannot draw blood and not test it." The referrals create a two-tier system: those who can afford private tests get monitored; those who cannot go blind—literally, as hypertensive retinopathy sets in, or silently, as kidneys fail.

Out-of-Pocket Spiral: Lab Costs Eat Into Food and Transport

For tea pickers earning near the minimum wage, every shilling counts. Monthly spending on lab tests for hypertensive patients in Kericho averages 400 to 800 KES, according to a small survey by the Kenya Hypertension Society. That might not sound like much, but it's equivalent to a day's wage for many pickers. A single creatinine test at a private lab costs 500 KES—the same as a day's pay for Mary. When money is tight, patients skip tests. A study from Nairobi in 2023 found that 40% of hypertensive patients tested irregularly, with cost cited as the main barrier. In rural areas like Kericho, the proportion is likely higher.

Private labs are concentrated in towns, not rural areas. Mary's nearest private lab is in Kericho town, a 30-minute matatu ride. For pickers on more remote estates, the trip can take over an hour each way, costing 200 KES or more in transport. Add the test fee, and a single monitoring visit can cost 700 to 1,000 KES—more than 10% of monthly income. The consequence is that many patients simply stop testing. They continue taking their amlodipine, but without knowing whether their blood pressure is controlled or if their kidneys are being damaged. "We call it flying blind," said Dr. Omondi. "The patient gets a prescription, but no one checks if it's working. That's not care."

The 2023 Free Screening Promise That Never Arrived

In 2023, Kenya launched a Universal Health Coverage pilot program in four counties: Kisumu, Nyeri, Machakos, and Isiolo. The plan was to offer free blood pressure checks and basic lab tests at public facilities, part of a broader push to reduce out-of-pocket spending. Kericho was not included. The pilot was supposed to be a test case for national rollout, but two years later, it remains limited. The pilot has faced its own challenges. In Kisumu, supplies for screening were diverted or delayed. Community health workers, who were supposed to conduct home visits and BP checks, went unpaid for months. "The program was announced with great fanfare, but the implementation has been patchy," said Dr. Grace Wanjiku, a health economist at the University of Nairobi. "Kericho was left out entirely, so patients there never even got the promise."

For Mary and others in Kericho, the pilot's exclusion means continued reliance on private labs. "We heard on the radio that the government would pay for tests," Mary said. "But when I went to the clinic, they said it was not for our county." Community health workers in Kericho are supposed to be the link between patients and the health system, but they are unpaid and demotivated. A 2024 assessment found that only 30% of community health workers in the county had received any stipend in the previous year. Without them, screening rates remain low, and patients like Mary only come to the clinic when they feel sick—by which time complications may have set in.

When Medicines Are Free but Monitoring Costs a Fortune

Kenya's public health system has made progress on medicines. First-line hypertension drugs—amlodipine, hydrochlorothiazide, and enalapril—are available free at public clinics. Patients can walk in, get a prescription, and leave with a month's supply at no cost. That is a significant achievement. But it is incomplete. Without regular monitoring, the drugs may be ineffective or even dangerous. Hypertension is a silent disease. Patients often feel fine even when their blood pressure is dangerously high. The only way to know if treatment is working is to measure blood pressure and check for end-organ damage through lab tests. "You cannot manage hypertension by handing out pills," said Dr. Omondi. "You need to titrate doses based on response. That requires labs."

Kidney damage from untreated hypertension is particularly insidious. It progresses without symptoms until the kidneys fail. Dialysis, the only option for end-stage renal disease, costs roughly 10,000 to 15,000 KES per session—more than a month's income for most tea pickers. The irony is that simple, cheap tests can detect early kidney damage. A urine dipstick test for protein costs about 20 KES and can be done at a clinic. A serum creatinine test costs about 100 KES in bulk reagent pricing. But those prices are only realized when the public system procures them centrally. When patients buy them individually from private labs, the markup is huge.

Cheaper Alternatives: Community-Based BP Checks Save Money

There are cheaper ways to monitor hypertension. In Kisumu, a peer-led community screening program trained community health workers to use validated blood pressure cuffs and simple urine dipsticks. The program, run by the non-profit organization Health for All, reduced the need for lab visits by half. Patients whose BP was well-controlled could be monitored at home; only those with elevated readings were referred for lab tests. The cost per screen was roughly 30 KES—a fraction of the 500 KES for a private lab visit. "It's not perfect," said Sarah Atieno, a community health worker in Kisumu who participated in the program. "But it catches people early. We have seen many patients who did not know they had high BP." The program also trained patients to check their own BP at home using affordable devices, which cost about 3,000 KES once.

Scaling such programs to Kericho would be relatively cheap. The county government could train existing community health workers—there are roughly 1,500 in the county—to use cuffs and dipsticks. The cost of cuffs and dipsticks for a year would be a few million shillings, a fraction of the county health budget. But the funding is not allocated. "We have the people and the will," said a county health official who asked not to be named. "But the money goes to other priorities."

Another approach is mobile health units. In neighboring Nandi County, a pilot project used a van equipped with a BP cuff, a glucometer, and a small centrifuge for basic labs. The van visited tea estates on a rotating schedule, offering free screening and lab tests. Over six months, it screened 4,200 workers and detected 890 new cases of hypertension. The cost per worker was 150 KES—still a fraction of private lab costs. But the pilot ended when donor funding ran out. "It worked, but it wasn't sustainable without county support," said Dr. Omondi, who evaluated the project. "The county didn't budget for it."

Without community-based monitoring or mobile units, patients like Mary are left with a stark choice: pay for private labs or risk uncontrolled hypertension. Many choose the latter. Mary says she has skipped tests for the past four months because she needed the money for school fees. "I know I should test," she said. "But when I have to choose between the test and my children's education, I choose the school fees."

What Needs to Change: Reagents, Not Rhetoric

The solution is not complicated. County health budgets must allocate a specific line item for consumables—reagents, test strips, batteries for cuffs. Currently, consumables are often lumped into a general supplies budget that gets raided for other needs. A dedicated fund, managed at the facility level, could ensure that reagents are always in stock. Centralized procurement of reagents could also cut costs. Kenya's Kenya Medical Supplies Authority (KEMSA) already procures drugs and supplies for public facilities, but it is notoriously inefficient. Reforms to KEMSA, combined with better forecasting at the county level, could ensure that labs are never without reagents for months on end.

Task-shifting is another option. Nurses at dispensaries can be trained to perform basic lab tests—urine dipsticks, finger-stick glucose, and even creatinine using point-of-care devices. This would reduce the need to refer patients to distant labs. In 2024, the Ministry of Health approved a new cadre of "community health assistants" who could perform these tests, but training has not yet started in Kericho. "The policy is there, but the implementation is slow," said Dr. Wanjiku. "We need to move from policy to action."

Finally, the county government could negotiate with private labs to offer subsidized rates for hypertensive patients. In a pilot in Nakuru County, the government partnered with a chain of private labs to offer creatinine tests at 200 KES for registered hypertensive patients, down from 500 KES. The program covered 3,000 patients in its first year. "It's not free, but it's better than nothing," said a county health official involved in the program. "The key is to reduce the financial barrier."

These changes require political will and sustained funding. Without them, hypertensive farm workers in Kericho will continue to pay for private lab tests they cannot afford, while public clinic cuffs gather dust. The next step is for the Kericho County Health Department to present a budget amendment to the county assembly, allocating at least 5 million KES for consumables and community health worker stipends in the next fiscal year. Citizens can attend public budget hearings to demand this allocation. Without such action, the gap between policy and practice will continue to widen.

This article is for informational purposes only and does not constitute medical advice. Readers with hypertension should consult a qualified health professional for diagnosis and treatment.